Table 2.
Clinical Trial Results of GDC-0449, Nab-paclitaxel and Bevacizumab
| Investigator | Phase | Patient numbers | Drug combined | Results | References |
|---|---|---|---|---|---|
| GDC-0449 | |||||
| Lorusso et al. | I/II | 68 solid tumor (8 PC) | Monotherapy | 20 response, 14 SD (no PC), 8 PD | [159] |
| Nab-paclitaxel | |||||
| Chien et al. | I | 25 solid tumors(2 PC) | Lapatinib | 65% PR or SD (no pancreatic cancer pa- tients) | [160] |
| Hosein et al. | II | 19 PC (progressed on gemcit- abine) | Monotherapy | 6 mo OS 58%, median OS 7.3 mo, median PFS 1.6 mo, 1 pt PR, 6 pts SD, 12 PD | [152] |
| Isacoff et al. | Pilot | 28 PC (advanced) | 5-FU (low dose), leucovorin, oxaliplatin, bevacizumab | 1 CR, 13 PR, OS>8 months | [154] |
| Thappliya | I/II | 13 PC (unresectable/borderline resectable) | Gemcitabine | 9 PD, 3 SD, 1 PD, EORTC PET response: 7/10 PR, 3/10 SD | [153] |
| Bevacizumab | |||||
| Berlin et al. | II | 25 PC (resected tumor) | Gemcitabine, capecitabine, radiation | At 2 years: DFS 22%, OS 37% | [22] |
| Watkins et al. | I/II | 39 PC (advanced) | Gemcitabine, capecitabine, erlotinib | Radiological response 23%, median PFS 8.5 mo, median OS 12.8 mo Median & 1 year survival 11.1 mo & 49% (pts with metastasis), 14.8 mo & 89% (pts with local advanced) |
[102] |
| Martin et al. | II | 39 PC (advanced) | Gemcitabine, 5-FU | Freedom from progression in 53% pts (24 weeks), 24% PR, 47% SD, mean time to progression 8.1 mo, median survival 10.7 mo | [161] |
Abbreviations: PC, pancreatic cancer, PR, partial response, SD, stable disease, OS, overall survival, DFS, disease-free survival, PD, progressive disease, PFS, progression free survival.